Background {#Sec1}
==========

In both developed and developing countries, age-related macular degeneration (AMD) is the main cause of vision loss in the elderly people \[[@CR1], [@CR2]\]. By 2050, about 17.8 million people will be affected by AMD \[[@CR3]\]. AMD's visual loss is due to dead/non-functional photoreceptor cells and potential retinal pigment epithelium cells \[[@CR4]\]. In clinical practice, early dryness that can develop into geographic atrophy (atrophic, non-exudative) and wet (exudative) AMD characterized by choroidal neovascularization (CNV) are two forms about AMD \[[@CR5], [@CR6]\].

Age, race, family history, smoking and sun exposure are common risk factors \[[@CR7], [@CR8]\]. Another main factor in the etiology of AMD is genetic susceptibility \[[@CR9]\]. A genome-wide association study (GWAS) in 2005 confirmed the association between AMD risk and genetic variations, suggesting that AMD is a polygenic disease \[[@CR10]\], and in the following 15 years triggered many studies involving AMD genetic association \[[@CR11]--[@CR13]\]. So far, polymorphism about age-related maculopathy susceptibility 2 (AMRS2) rs10490924, complement factor H (CFH), complement 2 (C2)/complement factor H (CFB), complement component C3 and apolipoprotein E (APOE) haplotypes have been demonstrated as associated factors with susceptibility to AMD \[[@CR14]--[@CR18]\].

As we all known, VEGF is contributed to the progression of wet AMD, because angiogenesis and the formation of vascular permeability can lead to fluid leakage in blood vessels, and eventually lead to loss of vision \[[@CR19]\]. Anti-VEGF drugs (eg: ranibizumab and bevacizumab) have been widely used in clinics \[[@CR20], [@CR21]\]. In addition, they have been shown to be effective in slowing the development of CNV, however, individual differences and shorter treatment time have been observed \[[@CR22]\]. It is assumed that genetic factors may be involved in this period of heterogeneous response, such as variants of complement factor F (CHF), VEGFA, ARMS2 and high-temperature requirement factor A1 (HTRA1) \[[@CR23]--[@CR26]\].

HTRA1 regulates the transforming growth factor-β (TGF-β), insulin-like growth factor, and its binding protein, which is considered as regulators for cell proliferation, angiogenesis and extracellular matrix deposition. Furthermore, the inhibition of TGF-β may result in the overexpression of HTRA1 gene in wet AMD \[[@CR27]\] (<https://www.ncbi.nlm.nih.gov/gene/5654>).

One of common polymorphisms in HTRA1 gene is rs11200638 (wide allele G to mutation allele A) \[[@CR28]\]. The A-allele can influence the overexpression of HTRA1 protein, which may affect the integrity of Bruch's membrane and lead to promote the progression of CNV stage \[[@CR29]\].

In view of the above, we are aware of the critial role of HTRA1 gene and its common rs11200638 polymorphism, and we conducted a comprehensive summary using meta-analysis methods, including 28 different publications (33 case-control studies) \[[@CR26], [@CR30]--[@CR57]\].

Methods {#Sec2}
=======

Search strategy and criteria {#Sec3}
----------------------------

Relative studies from PubMed and Wanfang databases before 27th Jan, 2020 were searched. The keywords were "age-related macular degeneration," "AMD," "polymorphism or variant," and "HTRA1 or high-temperature requirement factor A1." Included criteria were according with as follows: (1) studies were focused on the correlation between AMD and rs11200638 polymorphism; (2) studies were all case-control and retrospective studies, and (3) the (AA, AG, and GG) genotypes both in case and control groups must be listed in Tables. Excluded criteria were consistent with as follows: (1) just case samples were shown in studies; (2) the numbers for genotypes did not shown in Tables, and (3) some duplications studies \[[@CR58]\]. After the above conditions of the layer-by-layer screening exclusion, finally, 35 different articles were identified.

Data extraction {#Sec4}
---------------

Two authors (Ying Liu and Dong Wei) independently screened all papers that according using above criteria. The basic information collected from each study contains the first author, year of publication, country source for corresponding authors, race type, Hardy-Weinberg equilibrium (HWE) for control group, detecting methods and AMD disease types (dry and wet AMD) \[[@CR58]\]..

Statistical analysis {#Sec5}
--------------------

Odds ratios (OR) with 95% confidence intervals (CI) were applied to assess associations for rs11200638 polymorphism and AMD \[[@CR58], [@CR59]\]. The statistical significance of the OR was evaluated by the *Z*-test \[[@CR60]\]. The heterogeneity among studies was calculated using the *Q*-test. Mantel-Haenszel (fixed-effects model) was selected, when *P*-value for heterogeneity is more than 0.1, otherwise, the DerSimonian-Laird (random-effects model) was applied \[[@CR61], [@CR62]\]. Five genetic models were adopt: AA vs. AG + GG, A vs. G, AA + AG vs. GG, AA vs. GG and AG vs. GG. The stability of results was assessed by sensitivity analysis. The HWE of control group was assessed by the Pearson's χ^2^ test \[[@CR63]\]. The publication bias was appraised by both Begg's test and Egger's test \[[@CR64]\]. All statistical calculation were performed through Stata software (version 10.0, StataCorp LP, College Station, TX, USA) \[[@CR59]\]. The power for sample size was calculated by Power and Sample Size Calculation Program \[[@CR65]\].

### Gene-gene interaction involved HTRA1 from a network {#Sec6}

The network of gene-gene interactions for HTRA1 gene was shown by String online server to more complete understanding of the role of HTRA1 in AMD \[[@CR66]\].

Results {#Sec7}
=======

Study searching and their basic information {#Sec8}
-------------------------------------------

A number of 262 papers were garnered by a document from the PubMed (222 titles) and Wanfang (40 titles) databases. One hundred seventy-eight articles were deleted after reading over the abstract sections (Fig. [1](#Fig1){ref-type="fig"}). Forty-one articles were excluded due to duplication (7), meta-analysis or systematic analysis (26), clinical trial (10), randomized controlled trial (6). Finally, 35 different articles \[[@CR26], [@CR30]--[@CR57], [@CR67]--[@CR71]\] were selected, including 38 studies about HTRA1 gene rs11200638 polymorphism and AMD risk (Table [1](#Tab1){ref-type="table"}) and 27 case-control studies about HTRA1 gene rs11200638 polymorphism and wet or dry AMD risk (Table [2](#Tab2){ref-type="table"}). Five case-control studies \[[@CR67]--[@CR71]\] were not consistent with HWE in control groups. To make our analysis to more strict, we deleted above five studies, so there were about 33 case-control studies (8101 cases and 7215 controls) for the whole AMD \[[@CR26], [@CR30]--[@CR57]\], and 22 case-control studies for wet or dry (3938 cases and 4427 controls) studies \[[@CR26], [@CR30], [@CR31], [@CR33], [@CR34], [@CR40], [@CR41], [@CR43], [@CR44], [@CR46]--[@CR48], [@CR51], [@CR53]--[@CR56]\]. The A-allele frequency from case group was observed as higher in control individuals (54.2% vs. 36.5%) (Fig. [2](#Fig2){ref-type="fig"}, Supplementary Table [1](#MOESM1){ref-type="media"}). Nineteen studies were Asian samples, and 14 from Caucasian population; source of control in 22 studies were hospital-based (HB), and 11 were from population-based (PB); 17 case-control studies were about wet AMD disease, and 5 were about dry disease. Additional, the Minor Allele Frequency (MAF) about five main worldwide populations in the 1000 Genomes Browser was shown in Fig. [3](#Fig3){ref-type="fig"}: Global (0.290); East Asian (EAS = 0.411); European (EUR = 0.194); African (AFR = 0.257); American (AMR = 0.250); and South Asian (SAS = 0.340) (Supplementary Table [1](#MOESM1){ref-type="media"}). Fig. 1Flowchart for the search strategy was used to identify associated studies for rs11200638 polymorphism and AMD riskTable 1Characteristics of included studies in HTRA1 rs11200638 polymorphism and AMD riskAuthorYearCountryEthnicitytypeCaseControlSOCCasesControlsHWEGenotype**AAAGGGAAAGGG**Tian2012ChinaAsianAMD532468HB255193841042241400.423Typer 4.0 softwareRuamviboonsuk2017ThailandAsianwet3771073PB125164881464904370.643InfiniumOmniExpressExome-8 v1.3 platformChu2008ChinaAsianwet144126HB7652163169260.276PCR-RFLPLosonczy2011HungaryCaucasianAMD10395HB235030349430.133PCR-RFLPTuo2008USACaucasianAMD142132PB336049751740.638PCR-RFLPTuo2008USACaucasianAMD330191PB6316410312731060.904PCR-RFLPTuo2008USACaucasianAMD272555PB15122135201863490.431PCR-RFLPTuo2008USACaucasianAMD4622PB2152916150.696PCR-RFLPChan2007USACaucasianAMD5213HB1427110850.109RT-PCRKanda2007USACaucasianAMD457280HB10218317211901790.94RT-PCRCheng2013ChinaAsianwet9393HB5230112142300.395SequencingLiang2012ChinaAsianwet161150HB6183173072480.751SequencingJiang2008ChinaAsianwet159140HB9947133167420.662SequencingLee2010KoreaAsianwet137187HB57592135100520.283SequencingLin2008China-TaiwanAsianAMD9590HB533391947240.651SequencingKaur2008IndiaAsianAMD229184HB9089502185780.765SequencingXu2007ChinaAsianwet121132HB5652132464440.931SequencingTam2008China-Hong KongAsianwet163183HB9451183890550.916SequencingMori2007JapanAsianAMD123133HB4552262257540.298SequencingAskari2015IranAsianAMD120120HB5842201266420.057SequencingLana2018BrazilCaucasianAMD204166HB7389422277670.987SequencingKaur2013IndiaAsianAMD198145PB8470441767610.829SequencingNg2016Hong KongAsianwet194183PB10963223890550.916SequencingKaur2013IndiaCaucasianAMD616426PB130292194171382710.913SequencingChen2013ChinaAsianAMD158157HB2874562177590.599TaqManKondo2007JapanAsianAMD7394HB293951640380.334TaqManLeveziel2007FranceCaucasianwet118116HB325729541700.743TaqManWeger2007AustriaCaucasianwet242157PB6710867850990.609TaqManLu2007ChinaAsianwet90106HB53343156328\< 0.05PCR-RFLPCruz-González2013SpainCaucasianAMD12191HB29603261219\< 0.05PCR-RFLPMohamad2019MalaysiaAsianwet145145HB794719488215\< 0.05PCR-RFLPYang2010ChinaAsianwet109150HB314533305070\< 0.05PCR-RFLPChen2008USACaucasianAMD776294HB13140024510128156\< 0.05SequencingZeng2011ChinaCaucasianAMD1335509PB244641450211813070.374SNaPshotLi2015ChinaAsianAMD146145HB7354194474270.674MassARRAY MALDI-TOFYang2018ChinaAsianAMD201201HB103742442100590.975MassARRAY MALDI-TOFMatuskova2020Czech RepublicCaucasianwet307191HB69148909661160.921SNaPshot Multiplex-SystemFritsche2008GermanyCaucasianAMD760549PB152344264221743530.923Multiplex PCR*HB* hospital-based; *PB* population-based; *SOC* source of control; *PCR-RFLP* polymerase chain reaction followed by restriction fragment length polymorphism; *RT-PCR* real-time PCR; *MALDI-TOF* polymerase chain reaction--matrix-assisted laser desorption/ionization time-of-flight; *HWE* Hardy--Weinberg equilibrium of control groupTable 2Characteristics of included studies in HTRA1 rs11200638 polymorphism and wet/dry AMD risk, respectivelyAuthorYearCountryEthnicitytypeCaseControlSOCCasesControlsHWEGenotypeAAAGGGAAAGGGLin2008China-TaiwanAsiandry5290HB281951947240.651SequencingChan2007USACaucasiandry1813HB41040850.109RT-PCRMori2007JapanAsiandry19116HB478541700.743SequencingAskari2015IranAsiandry32120HB111291266420.576SequencingRuamviboonsuk2017ThailandAsianwet3771073PB125164881464904370.643InfiniumOmniExpressExome-8 v1.3 platformCheng2013ChinaAsianwet9393HB5230112142300.395SequencingNg2016Hong KongAsianwet194183PB10963223890550.915SequencingLiang2012ChinaAsianwet161150HB6183173072480.75SequencingChu2008ChinaAsianwet144126HB7652163169260.276PCR-RFLPJiang2008ChinaAsianwet159140HB9947133167420.662SequencingLee2010KoreaAsianwet137187HB57592135100520.283SequencingLin2008China-TaiwanAsianwet4390HB251441947240.651SequencingXu2007ChinaAsianwet121132HB5652132464440.931SequencingTam2008China-Hong KongAsianwet163183HB9451183890550.916SequencingChan2007USACaucasianwet3113HB81670850.109RT-PCRLeveziel2007FranceCaucasianwet118116HB325729541700.743TaqManMori2007JapanAsianwet104116HB414518541700.743SequencingAskari2015IranAsianwet88120HB4730111266420.576SequencingWeger2007AustriaCaucasianwet242157PB6710867850990.609TaqManLu2007ChinaAsianwet90106HB53343156328\< 0.05PCR-RFLPMohamad2019MalaysiaAsianwet145145HB794719488215\< 0.05PCR-RFLPYang2010ChinaAsianwet109150HB314533305070\< 0.05PCR-RFLPChen2008USACaucasianwet470294HB7624514910128156\< 0.05SequencingChen2008USACaucasiandry306294HB551559610128156\< 0.05SequencingZeng2011ChinaCaucasiandry341509PB60166115211813070.374SNaPshotZeng2011ChinaCaucasianwet994509PB184475335211813070.374SNaPshotMatuskova2020Czech RepublicCaucasianwet307191HB69148909661160.921SNaPshot Multiplex-SystemFig. 2The MAF of minor-allele (mutant-allele) for HTRA1 gene rs11200638 polymorphism from the 1000 Genomes online database and present analysis. EAS: East Asian; EUR: European; AFR: African; AMR: American; SAS: South AsianFig. 3Frequency about A-allele for the rs11200638 polymorphism among cases or controls by ethnicity

Quantitative synthesis {#Sec9}
----------------------

### Total analysis {#Sec10}

Increasing relationships were found for rs11200638 and AMD risk in all models (eg: AA vs. GG: OR = 5.45, 95CI% = 4.26--6.98, *P* \< 0.001) (Table [3](#Tab3){ref-type="table"}). In order to make this study more convincing and reliable, we detected five studies, which were not according with HWE, finally, we tested the 33 case-control studies. Also significantly increasing correlations were observed in whole models \[for example: allelic contrast: OR (95%CI): 2.56(2.34--2.80), *P* \< 0.001; AA+AG vs. GG: OR (95%CI): 2.80 (2.49--3.15), *P* \< 0.001\] (Fig. [4](#Fig4){ref-type="fig"}) (Table [3](#Tab3){ref-type="table"}). Table 3Results of the meta-analysis on HTRA1 rs11200638 polymorphism and AMD risk in total and types of subgroupsVariablesNCase/A-allele vs. G-alleleAG vs. GGAA+AG vs. GGAA vs. GGAA vs. AG + GGControlOR(95%CI) *P*~h~*P*OR(95%CI) *P*~h~*P*OR(95%CI) *P*~h~*P*OR(95%CI) *P*~h~*P*OR(95%CI) *P*~h~*P*Total388582/74522.39(2.12--2.69)0.000 0.0001.91(1.69--2.16)0.000 0.0002.63(2.30--3.01)0.000 0.0005.45(4.26--6.98)0.000 0.0003.75(3.04--4.63)0.000 0.000HWE338101/72152.56(2.34--2.80)0.000 0.0001.98(1.76--2.23)0.001 0.0002.80(2.49--3.15)0.000 0.0006.13(5.09--7.38)0.000 0.0004.10(3.55--4.73)0.000 0.000Ethnicity Asian193424/40042.51(2.22--2.83)0.000 0.0001.67(1.47--1.88)0.167 0.0002.68(2.25--3.19)0.009 0.0005.36(4.31--6.66)0.003 0.0003.70(3.16--4.35)0.009 0.000 Caucasian144677/32112.63(2.29--3.02)0.000 0.0002.37(2.15--2.61)0.140 0.0002.94(2.51--3.45)0.004 0.0007.52(5.62--10.07)0.014 0.0005.00 (3.91--6.40)0.070 0.000SOC HB223589/32732.56(2.28--2.88)0.000 0.0001.86(1.58--2.19)0.025 0.0002.81(2.38--3.31)0.005 0.0005.99(4.74--7.59)0.001 0.0003.93(3.31--4.68)0.005 0.000 PB114512/339422.55(2.18--2.99)0.000 0.0002.16(1.84--2.53)0.021 0.0002.80(2.35--3.35)0.001 0.0006.37(4.64--8.76)0.001 0.0004.43(3.41--5.75)0.009 0.000AMD type Wet173476/35793.03(2.59--3.55)0.000 0.0002.11(1.81--2.46)0.138 0.0003.40(2.90--3.99)0.073 0.0007.65(5.73--10.21)0.009 0.0004.65(3.72--5.82)0.008 0.000 Dry5462/8482.36(1.71--3.24)0.750 0.0001.33(0.76--2.32)0.705 0.3162.08(1.24--3.48)0.618 0.0056.01(3.05--11.87)0.889 0.0004.77(2.79--8.16)0.964 0.000Genotyping Others53004/25992.55(2.22--2.94)0.027 0.0002.14(1.67--2.73)0.006 0.0002.85(2.38--3.43)0.055 0.0006.25(4.26--9.15)0.005 0.0004.18 (3.14--5.57)0.033 0.000 Sequencing142613/23322.84(2.61--3.09)0.237 0.0002.08(1.81--2.41)0.252 0.0003.19(2.79--3.65)0.710 0.0007.00(5.84--8.39)0.677 0.0004.51(3.90--5.21)0.169 0.000 TaqMan4591/5242.66(1.43--4.94)0.000 0.0022.79(1.31--5.91)0.000 0.0083.61(1.52--8.60)0.000 0.0047.52(2.05--27.68)0.000 0.0023.86(1.66--8.98)0.002 0.002 PCR-RFLP61037/11211.98(1.72--2.26)0.105 0.0001.76(1.45--2.14)0.611 0.0002.08(1.73--2.50)0.411 0.0004.30(2.51--7.35)0.073 0.0003.33(2.09--5.31)0.095 0.000 RT-PCR2509/2932.91(2.30--3.69)0.755 0.0002.08(1.51--2.86)0.643 0.0002.90(2.15--3.92)0.734 0.0009.83(5.18--18.65)0.817 0.0007.19(3.84--13.45)0.806 0.000 MassARRAY MALDI-TOF2347/3462.18(1.39--3.49)0.043 0.0011.46(0.95--2.24)0.213 0.0882.22(1.13--4.38)0.099 0.0213.84(1.53--9.63)0.044 0.0043.05(1.78--5.23)0.097 0.000*P*~h~: value of *Q*-test for heterogeneity test; *P*: *Z*-test for the statistical significance of the ORFig. 4Forest plot of AMD risk associated with HTRA1 gene rs11200638 polymorphism (A-allele vs. G-allele) by ethnicity subgroup

### Subgroup analysis {#Sec11}

Coming up, we all know that the frequency of A-allele in different races was not the same, so we tried to analysis the relationships by ethnicity subgroups in further, which indicated an incremental statistically association between this polymorphism and both in Asians \[OR(95% CI) = 2.51(2.22--2.83), *P*~*(*heterogeneity)~ \< 0.001, *P* \< 0.001 in allelic contrast, Fig. [4](#Fig4){ref-type="fig"}; AA vs. AG + GG: OR (95% CI) = 3.70(3.16--4.35), *P*~*(*heterogeneity)~ = 0.009, *P* \< 0.001\] and Caucasian populations \[OR (95% CI) = 2.94(2.51--3.45), *P*~*(*heterogeneity)~ \< 0.001 in dominant model; OR = 2.37, 95% CI = 2.15--2.61, *P*~*(*heterogeneity)~ \< 0.001 in heterozygote comparison; allelic comparison, OR = 2.63, 95% CI = 2.29--3.02, *P*~heterogeneity~ \< 0.001, *P* \< 0.001, Fig. [4](#Fig4){ref-type="fig"}) (Table [3](#Tab3){ref-type="table"}). In addition, regular analysis by source of control, also similar results were detected in both PB and HB studies \[AG vs. GG: OR (95% CI) = 1.86(1.58--2.19), *P*~heterogeneity~ = 0.025, *P* \< 0.001 in HB; AG vs. GG: OR (95% CI) = 2.16(1.84--2.53), *P*~*(*heterogeneity)~ = 0.021, *P* \< 0.001 in PB\] (Table [3](#Tab3){ref-type="table"}) (Fig. [5](#Fig5){ref-type="fig"}). AMD have different types and stages, the different of clinical presentation for dry and wet AMD is completely different, so we firmly believed that the correlations existed should be evaluated separately, significant positive associations were found both for dry (eg. AA+AG vs. GG: OR (95% CI) = 2.73(2.13--3.51), *P*~*(*heterogeneity)~ = 0.498, *P* \< 0.001, Fig. [6](#Fig6){ref-type="fig"}a) and wet AMD (for example in AA+AG vs. GG model: OR = 3.40, 95% CI = 2.90--3.99, *P*~heterogeneity~ = 0.073, *P* \< 0.001, Fig. [6](#Fig6){ref-type="fig"}b). Finally, we tried to in each method, whether associations may exist in our analysis, we found some positive results in some methods (such as in AA vs. GG model: OR = 7.52, 95% CI = 2.05--27.68, *P*~heterogeneity~ \< 0.001, *P* = 0.002 about TaqMan; OR = 4.30, 95% CI = 2.51--7.35, *P*~heterogeneity~ = 0.073 about PCR-RFLP, OR = 3.84, 95% CI = 1.53--9.63, *P*~heterogeneity~ = 0.044 about MassARRAY MALDI-TOF, Fig. [7](#Fig7){ref-type="fig"}a; OR = 7.00, 95% CI = 5.84--8.39, *P*~heterogeneity~ = 0.677 about sequencing, OR = 9.83, 95% CI = 5.18--18.65, *P*~heterogeneity~ = 0.817 about sequencing RT-PCR, Fig. [7](#Fig7){ref-type="fig"}b) (Table [3](#Tab3){ref-type="table"}). Fig. 5Forest plot of AMD risk associated with HTRA1 gene rs11200638 polymorphism (AG vs. GG) by source of control subgroupFig. 6Forest plot of AMD risk associated with HTRA1 gene rs11200638 polymorphism (AA+AG vs. GG) by AMD type subgroup. **a**: wet AMD; **b**: dry AMDFig. 7Forest plot of AMD risk associated with HTRA1 gene rs11200638 polymorphism (AA vs. GG) by genotyping methods subgroup. **a**: random model; **b**: fixed model

Bias diagnosis for publication and sensitivity analysis {#Sec12}
-------------------------------------------------------

Begg's funnel plot and Egger's test were applied to assess publication bias. At beginning, the funnel plots seemed asymmetrical in allele comparison for rs11200638 by Begg's test, suggesting no publication bias was existed. Then, Egger's test was applied to assess the funnel plot symmetry. As a result, no publication bias was observed \[eg. allelic contrast, Egger's test (*t* = 0.89, *P* = 0.38); Begg's test (*z* = 0.85, *P* = 0.396), Supplementary Figure [1](#MOESM2){ref-type="media"}A,B\] (Table [4](#Tab4){ref-type="table"}). Table 4Publication bias tests (Begg's funnel plot and Egger's test for publication bias test) for HTRA1 rs11200638 polymorphismEgger's testBegg's testGenetic typeCoefficien*t*Standard error*tP* value95%CI of intercept*zP* valueA-allele vs. G-allele0.2110.9240.230.820(−1.673--2.096)0.420.676AG vs. GG−0.0310.500−0.060.951(−1.051--0.989)0.290.768AA+AG vs. GG−0.0450.532−0.080.933(−1.130--1.040)0.260.792AA vs. GG0.2970.3820.780.441(−0.481--1.076)0.360.722AA vs. AG + GG0.3650.4380.830.412(−0.529--1.258)0.600.546

To assess the power and stability of whole study and each study, the sensitive analysis was adopt to carry out, as a result, no significant showing were found (Supplementary Figure [2](#MOESM3){ref-type="media"}).

Gene-gene network from string online site {#Sec13}
-----------------------------------------

The HTRA1 gene may interacts with numerous genes from String online server (Fig. [8](#Fig8){ref-type="fig"}). Fig. 8Interactions network about human HTRA1 gene and other related genes from String server. ACAN: aggrecan core protein; ARMS2: age-related maculopathy susceptibility; CLPP: ATP-dependent Clp protease proteolytic subunit; CTRC: chymotrypsin-C; YME1L1: ATP-dependent zine metalloprotease YME1L1; CFH: complement factor H; HSPD1: 60 kDa heat shock protein; RPL34: 60S ribosomal protein L34; CLPX: ATP-dependent Clp protease ATP-binding subunit clpX-like; PLEKHG4: Puratrophin-1

Discussion {#Sec14}
==========

Due to the severe consequences of vision loss caused by AMD, especially advanced AMD (atrophic/dry or neovascular/wet), it is necessary to study its etiology and mechanism, and then develop early diagnostic methods and effective treatments. Today, VEGF inhibitors have been widely regarded as effective drugs in clinical application for CNV (wet AMD) \[[@CR3], [@CR72], [@CR73]\]. Therefore, identifying some novel detection markers and target drugs for some different types of AMD is the focus of current and future research. In the introduction, we clarified that genetic factors may help us to search for AMD in potential high-risk groups, which can be prevented and treated in advance.

In our analysis, we selected the HTRA1 gene that can regulate certain growth factors. The rs11200638 polymorphism in HTRA1 is the most common single nucleotide polymorphism (SNP) and has been received attention. However, Kanda et al. \[[@CR35]\] demonstrated that there was no HTRA1 gene involved in AMD related SNPs, and its rs11200638 polymorphism did not appear to have an effect on the transcripts. Instead, they found a putative mitochondrial protein (LOC105378525) that may be expressed in the retina in the negative strand, which may be a candidate gene. In fact, they showed that rs11200638 and rs10490924 are in a strong linkage disequilibrium, which is a predicted non-synonymous A69S change in a protein named LOC105378525(LOC387715)/ARMS2. According to their research, rs10490924 was a strong candidate SNP associated with AMD risk, not rs11200638. In addition, Bonyadi et al. \[[@CR74]\] conducted a meta-analysis of rs10490924 and found that the combined cigarette smoking and rs10490924 polymorphism may have significant association with AMD risk. We believed rs10490924 was a valuable SNP for AMD, nevertheless, conclusions based on a single study may not be negated by the potential functions for HTRA1 and its SNPs, which need more evidences and support from published and future researches.

Mori et al. before all others reported the correlations for rs11200638 polymorphism and AMD \[[@CR47]\]. After that, researchers imitated similar works involving different ethnicities and different types about AMD. Nevertheless, each conclusion was indecipherable, even same population, though two published meta-analysis. As we all know, meta-analysis offers a method combining all related studies to acquire a powerful genetic effects for disease susceptibility \[[@CR75]\].

Two previous meta-analysis \[[@CR76], [@CR77]\] about rs11200638 polymorphism and AMD have been reported, however, each study has its limitations. For example, Tang et al. just included fourteen case-control studies, two studies \[[@CR67], [@CR69]\] were not consistent with HWE, and Tuo et al. actually reported four-source case-control studies, which shouldn't be combined together \[[@CR77]\]. Chen et al. also performed a same study in the same year including 14 case-control studies, similar limitations were existed \[[@CR76]\]. After year of 2008, newly added studies have been published, and to perfect the above deficiencies, we carried out a comprehensive analysis to come to a more convincing conclusion about HTRA1 gene rs11200638 polymorphism and AMD susceptibility.

Our current research is the comprehensive analysis about the associations between HTRA1 gene rs11200638 polymorphism and AMD, involving 8101 AMD samples and 7215 controls. Increased associations were found in the whole group, in Asian and Caucasian subgroups, source of control subgroup, and dry/wet sub-types of AMD, different genotyping methods (Sequencing, TaqMan, PCR-RFLP, RT-PCR and MassARRAY MALDI-TOF), which means that A-allele or AA genotype is the risk factor for AMD, in other words, if individuals carry on this SNP from peripheral blood test, which may indicate that it is possible to increase the occurrence of AMD for them in present time or at some point in the future. Therefore, this polymorphism may be helpful in screening vulnerable populations for AMD in advance. In addition, the power of present study was 1.00, which suggested our conclusions were stable and convincing.

In addition, the online String website was used to make a forecast several potential and functional genes associated with HTRA1. As a result, ten genes were predicted. Among them, the highest score of association was ACAN (0.943), however, so far, no research has been reported between this gene and AMD and interaction between this gene and HTRA1. Future research should be payed attention to above information, which may be in favor of AMD early detection/prevention and intervention. In other partners, ARMS2 and CFH have been shown to associate with AMD. Both *ARMS2* and *HTRA1* genes have a linkage disequilibrium, which is located nearby form 10q26 chromosome. ARMS2 rs10490924 was related to response to ranibizumab treatment among wet AMD patients \[[@CR70]\]. CFH gene T1277C polymorphism is strong associated with both wet and dry AMD and may be contribute to the inflammation in the pathogenesis of AMD \[[@CR78]\]. As for the rest interaction genes (CLPP, CTRC, YME1L1, HSPD1, RPL34, CLPX and PLEKHG4) both had moderate score and no literature to support. It seems that above ten genes associated with HTRA1 came from text mining scores, which were derived from the co-occurrence of gene/protein names in related abstracts. In addition, it was important considered the occurrence of the LOC105378525 (LOC387715) and its polymorphism (A69S, rs10490924) as the main factor for AMD reported by Kanda et al. (2007) \[[@CR35]\], which should be added in the network of HTRA1 related genes. In a word, we should deep explore these partners of HTRA1 gene, and gene-gene interactions in the development of AMD in the next step.

Some limitations should be declared. First of all, Mixed and African individuals should be paid more attention in future studies, which was vacant in present analysis. Second, analysis about gene-gene/gene-environment interactions should be added, because some specific environmental and lifestyle factors may influence associations between rs11200638 polymorphism and AMD (such as hypertension, familial history, age range, diabetes stage, smoking status). Third, vision is the most concerned-clinical indicator of AMD, future studies should include the value of the vision and analyze the relationships between rs11200638 polymorphism and the degree of visual impairment, which may help us to better detect disease progression.

Conclusion {#Sec15}
==========

In conclusion, our present analysis demonstrated HTRA1 rs11200638 polymorphism may play a risk factor for the susceptibility of AMD, larger and more comprehensive studies should be performed in the future.
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**Additional file 1: Table S1**. Allele Frequency from 1000 Genomes Browser and present study. **Additional file 2: Figure S1**. A: Begg's funnel plot for publication bias test (A-allele vs. G-allele). Each point represents a separate study for the indicated association. B: Egger's publication bias plot (A-allele vs. G-allele). **Additional file 3: Figure S2**. Sensitivity analysis between HTRA1 gene rs11200638 polymorphism and AMD risk (A-allele vs. G-allele).

AMD

:   Age-related macular degeneration

GWAS

:   Genome-wide association studies

HTRA1

:   High-temperature requirement factor A1

CNV

:   Choroidal neovascularization

VEGF

:   Vascular endothelial growth factor

AREDS

:   Age-Related Eye Disease Study

SNP

:   Single nucleotide polymorphism

HB

:   Hospital-based

PB

:   Population-based

SOC

:   Source of control

PCR-RFLP

:   Polymerase chain reaction followed by restriction fragment length polymorphism

MALDI-TOF

:   A chip-based matrix-assisted laser-desorption/ionization time-of-flight
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